- Home
- IONS vs ZG Comparison
IONS vs ZG Comparison
Compare IONS & ZG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IONS | ZG |
|---|---|---|
| Founded | 1989 | 2004 |
| Country | United States | United States |
| Employees | N/A | 7068 |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9B | 9.8B |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | IONS | ZG |
|---|---|---|
| Price | $74.88 | $45.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 26 |
| Target Price | ★ $92.73 | $79.82 |
| AVG Volume (30 Days) | ★ 1.6M | 825.2K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $17.77 |
| Revenue Next Year | $77.99 | $13.31 |
| P/E Ratio | ★ N/A | $499.11 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.79 | $39.14 |
| 52 Week High | $86.74 | $90.22 |
Technical Indicators
Market Signals| Indicator | IONS | ZG |
|---|---|---|
| Relative Strength Index (RSI) | 47.96 | 56.37 |
| Support Level | $69.85 | $41.00 |
| Resistance Level | $77.08 | $46.76 |
| Average True Range (ATR) | 1.99 | 1.89 |
| MACD | 0.16 | 0.89 |
| Stochastic Oscillator | 45.01 | 70.83 |
Price Performance
Historical ComparisonAbout IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
About ZG Zillow Group Inc.
Zillow Group Inc is a real estate technology company offering a digital platform that connects real estate customers with sellers, agents, loan officers, and other real estate-related professionals. With its tools and resources, Zillow helps real estate professionals grow their businesses, and for renters and housing providers, it offers a marketplace along with a set of end-to-end products and services to streamline applications, leases, payments, and more. The group operates various brands such as Zillow, Zillow Home Loans, Zillow Rentals, Zillow New Construction, Trulia, StreetEasy, Out East, HotPads, Follow Up Boss, ShowingTime, dotloop, and Zillow Closing. Its ecosystem spans the entire home journey from shopping to renting, buying, selling, and financing real estate.